Resectable Brain Tumors | Primary Research (KOL's Insight) | Market Intelligence | Epidemiology & Market Forecast-2035

With more than half of all clinical brain tumors being brain metastases, these tumors are the most prevalent. Surgical removal of brain metastases was once thought to be only a palliative procedure, but more recently, it has been demonstrated to play a more significant role in extending survival in carefully chosen patients. About 77,110 cases of brain tumors are diagnosed worldwide after 5 years. In the United States and Canada, the incidence of primary brain tumors is 17% of all cancers, and the incidence of all CNS tumors worldwide is 39%. Cancer cells that have spread to the brain cannot be treated with drugs. Failure of chemotherapy is linked to the blood-brain barrier's stability and tumor cells developing drug resistance. However, the majority of tumors that metastasize to the brain are resistant to chemotherapy, unlike small cell lung cancer, breast cancer, and lymphoma.

Description

With more than half of all clinical brain tumors being brain metastases, these tumors are the most prevalent. Surgical removal of brain metastases was once thought to be only a palliative measure, but recent research has shown that it can actually extend survival in carefully chosen patients. The morbidity related to lumpectomies has been reduced thanks to modern surgical techniques. There is still interest in the use of other surgical adjuvants to postpone or completely avoid the need for fractionated radiotherapy, despite the fact that randomized trials suggest the need for whole-brain radiation therapy after surgery. The use of various treatment modalities, particularly image-guided surgery, and stereotactic radiosurgery, enables medical professionals to concentrate on the treatment of brain metastases and thus offers a higher level of brain tumor control. As a result, the patient's status with regard to systemic disease is more important for overall survival.

Resectable Brain Tumors (Epidemiology)

After five years, there are roughly 77,110 cases of brain tumors worldwide. In the United States and Canada, the global incidence of all CNS tumors is 3.9, and primary brain tumors make up 1.7% of all cancers. While Caucasians had a higher rate of malignant tumors, African Americans had a higher rate of benign tumors. With notable differences, women with meningioma have a higher incidence of central nervous system tumors. Meningiomas, which make up 36.8% of all primary brain tumors, are the most frequent. With a worldwide incidence of 6 cases per 100,000 human years, gliomas are the most prevalent type of cancer, making up 75% of all cancers of the central nervous system. Of all cancer-related deaths worldwide, 2.71% are caused by central nervous system cancer. The only factors linked to ionizing radiation and neurofibromatosis, tuberous sclerosis complex, hereditary cancers, and other hereditary cancer syndromes have been identified as risk factors for developing brain tumors (Lynch and Lee Fraumeni). In general, adult mortality rates are higher than those of children. Anaplastic astrocytoma patients had a 5-year survival rate of 30%, whereas glioblastoma (GB) patients had a 5-year survival rate of 5.6% and 0.71%, respectively.

Resectable Brain Tumors -Current Market Size & Forecast Trends

The market for resectable brain tumors is expected to grow significantly, with the global brain tumor treatment market valued at around USD 5.5 billion in 2023 and projected to reach approximately USD 9.7 billion by 2030, reflecting a compound annual growth rate (CAGR) of 8.3%. This growth is driven by an increasing incidence of brain tumors, advancements in diagnostic technologies, and the development of new treatment options, including targeted therapies.

Cancer cells implanted in the brain are not responsive to drug therapy. Intact blood-brain barriers and tumor cells that have developed drug resistance are factors in chemotherapy failure. Chemotherapy is effective against small cell lung cancer, breast cancer, and lymphoma, but the majority of brain metastases are resistant to it. As a result, systemic disease, tumor type, and disease stage all affect treatment and management. Several chemotherapy drugs, such as cisplatin, cyclophosphamide, etoposide, teniposide, mitomycin, irinotecan, amphetamine, etoposide, isotope cyclophosphamide, temozolouramide, and temozolouramide, have been used to treat lung, breast, and melanoma brain metastases. When combined with whole brain radiation therapy (WBRT), 2-3 of these medications are typically used. The results of using this method are not encouraging. The median survival after lung, breast, and melanoma chemotherapy alone is approximately. 3.2-8 months. The survival time is roughly 3.5-13 months when chemotherapy and WBRT are used together. Chemotherapy cure rates can exceed 10%; partial response rates hover around 40%; and local control rates hover around 9%. For brain metastases, radiotherapy has grown in importance. Stereotactic radiosurgery and WBRT are both form of radiation therapy. For patients with multiple lesions, WBRT has been advised for a long time. Additionally, WBRT is advised for patients with a low Karnofsky score or a short-term prognosis. Other types of lung cancer and breast cancer are less sensitive to radiation, while melanoma and renal cell carcinoma are completely insensitive. Small cell lung tumors and germ cell tumors are particularly sensitive to radiation. Radiation-resistant lesions like non-small cell lung cancer, renal cell carcinoma, and melanoma are best treated with stereotactic radiosurgery (SRS). In particular for patients with breast metastases, it is frequently used in the management of cavity resection of brain metastases. Because whole brain radiation therapy, also known as EBRT, has long-term detrimental cognitive effects and is therefore less common in the second group of patients who have a higher chance of survival. Recidivism rates in this region range from 10-25%, despite improvements in SRS. After unsuccessful plastic surgery, there have been reports of a high rate of nervous system mortality, particularly in cases involving the brain that cannot be surgically duplicated. The median survival time following radiosurgery was 14.1 months.

Report Highlights

Resectable Brain Tumors - Current Market Trends

Resectable Brain Tumors - Current & Forecasted Cases across the G8 Countries

Resectable Brain Tumors - Market Opportunities and Sales Potential for Agents

Resectable Brain Tumors - Patient-based Market Forecast to 2035

Resectable Brain Tumors - Untapped Business Opportunities

Resectable Brain Tumors - Product Positioning Vis-a-vis Competitors' Products

Resectable Brain Tumors - KOLs Insight